The Only Non-Healthcare Winners Over the Past Two Years

This screen that I created in Exodus, pretty much tells it all.

The criteria is as follows.

The stock must be up over 20% YTD. +30% over the past year, and over 50% over the past two years. Market cap must be in excess of $1 billion and the average daily trading volume must be over 500k. In total, 160 stocks met this criteria, with the vast majority being black box, shrouded in black smoke, biotechs. Here are some non-biotech winners.

FL

CRM

DATA

MSCI

SEIC

WETF

FCAU

ORLY

MNST

STZ

Towards the end of the day, I dipped into my fucking cash horde to buy EGO, ONCE and GG. Don’t you worry about Le Fly missing the fucking rally. I’m up 24% for the year, bitch.

The last time you lectured me about finance, I ended up sticking a rail spike through your dense heads. Slow your roll and be mindful of whom you’re offering advice to, space alien magician (SAM), geared up in an Orbital Space Cannon (OSC), vaporizing clowns with my homo-hammer (HH).

It was a constructive close. My goals are to fleece those betting against gold and steadily reduce my basis in ONCE, so that I can get–the fuck– out of it at a profit.

Ciao (the most annoying form of goodbye)

Biotech stocks are screaming higher. Many of the names that I asked you to watch as a barometer of risk are careening higher, like EGRX and ESPR. Nevertheless, the over all tone of the market is somewhat milquetoast. Recall, I told you that Exodus was suggesting that the biotech sector was at the bottom of its “hybrid score” range, which is the predictive algorithms that places large bottles of champagne onto the granite kitchen countertops at House Fly.

.

.

.

We’re not there yet. I’m gonna wait to see how the market approaches the last half hour of trade. I am dying to put money to work.

ONCE is up today, after news hit the tape that KITE’s drug didn’t murder one of its test subjects. Naturally, it’s good to see my stocks up. Even GG is higher for the day, which is interesting for a whole other set of reasons.

Although the market is firming and my stocks are up, I do not have the confidence to reallocate funds towards new long positions. I will, however, add to existing position to manage my cost basis, like I did with ONCE on Friday.

Over the past two years, by far the biggest winners have been found in biotech. There have also been some hideous losers too. I am betting that if biotechs can reassert themselves as leaders again, the overall market will follow suit.

For now, my top picks are GG and ONCE.